EP0042

PreclinicalSmall molecule

EEllipses Pharma

EP0042 is one of 53 small molecule programs targeting Acute Myeloid Leukemia. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Acute Myeloid LeukemiaRecruiting

Acute Myeloid LeukemiaPreclinical

Recruiting

Competition

Competitive Landscape

255 competitors in Acute Myeloid Leukemia

#DrugCompanyPhaseTrials

Idamycin

Pfizer

Phase 3

59 2

Xospata

Astellas

Phase 3

24 3

Cerubidine

EEastern Cooperative Oncology Group

Phase 3

42 4

Mylotarg

WWyeth-Lederle Vaccines

Phase 3

38 5

Neupogen

EEastern Cooperative Oncology Group

Phase 3

31 6

Cerubidine

HHikma Pharmaceuticals LLC

Phase 3

30 7

Nexavar

Bayer

Phase 3

12 8

Cellcept

Roche

Phase 3

10 9

Busulfex

Trexall

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

PreclinicalRecruiting

Acute Myeloid Leukemia

NCT04581512

Clinical

Trials by Indication[1]

Acute Myeloid Leukemia1 trial

A Modular, Multipart, Multi-arm, Open-label, Phase I/IIa Study to Evaluate the Safety and Tolerability of EP0042 Alone and in Combination With Anti-cancer Treatments in Patients With Advanced Malignancies

Recruiting·EEllipses Pharma·Preclinical·NCT04581512·70 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for EP0042. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — EP0042 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for EP0042. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Ellipses Pharma company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: EEllipses Pharma

EP0042

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Acute Myeloid Leukemia1 trial

References

Drug Info

Quick Facts

Related News